Dr. S.F De Lacey

Dr. S.F De Lacey |Clyto Access

University of Zurich

Co-speaker

Expertise:

Biography: Sherrie Fluer De Lacey is a doctoral student, currently studying a PhD in Finance at the University of Zurich in Switzerland. Her research is geared towards understanding the economic impact of nanotechnology in society. She previously worked in the City of London as a financial analyst, developing proprietary trading algorithms. Whilst working in the City, Sherrie has helped raised capital totalling £7.5 million. Sherrie is also a founder of several startup companies, and serves as co-founder and Chief Financial Officer of Kids Trust. She holds a BSc in Politics from King’s College London, and an MSc in Economics from the London School of Economics. 

Presentation:

Title: Theranostic gold nanoparticles for paediatric neurosurgical applications in medulloblastoma

Abstract:

Medulloblastoma is the most common and highest grade primary brain tumour in children. Due to its aggressive nature within the brain tissue as well its tendency to metastasize and spread via the cerebrospinal fluid (CSF), complete and curative surgical resection is virtually impossible, giving it a relatively poor prognosis. Furthermore, the blood-brain-barrier (BBB) prevents many chemotherapeutic agents from reaching the intended site. In order to overcome these issues, we initially conducted exploratory research into using gold nanoparticles (AuNP) with cancer-targeting peptides as a “Trojan horse” to penetrate the BBB to deliver chemotherapeutic agents specifically to the tumour sites within the brain. Both in vitro and in vivo aspects of our study indicated a statistically significant decrease in cancer cells when platinum(IV)-loaded AuNPs were used, compared platinum(IV) alone and AuNPs alone. Furthermore, due to its high photoelectric absorption coefficient, we further discovered a synergistic cancer cell killing effect when radiotherapy was applied to AnNPs carrying a payload of chemotherapeutic drug. Results presented herein show an even higher rate of cell kill when platinum(IV)-loaded AuNPs were exposed to a therapeutic dose of radiation, compared to radiation alone and platinum(IV)-loaded AuNPs alone. Finally, we employed platinum(IV)-loaded AuNPs as computed tomography (CT) contrast agents using spectral diffusion algorithm. It was found that platinum(IV)-loaded AuNPs were able to localise to the tumour sites in both in vitro and in vivo models, with possible implications for it to be used in stereotactic neurosurgery. In conclusion, we have developed a novel multifunctional platform technology that can be used in drug delivery, a radiosensitizer in radiotherapy, and a molecular imaging agent for stereotactic surgery in paediatric medulloblastoma.

Related Conferences :

World Summit on Nanotechnology and Nanomedicine Research